A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1

References

• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581–92.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J Clin 2008;57:43–66.
   Web of Science ®Google Scholar
• Ytting H, Jensenius JC, Thiel S, Jensenius JC, Nielsen HJ. Serum MASP-2 in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res 2005;11:1441–6.
   PubMed Web of Science ®Google Scholar
• Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:308–19.
   Web of Science ®Google Scholar
• Baddi L, Benson AB. Adjuvant therapy in stage II colon cancer. Current approaches. The Oncologist 2005;10:325–31.
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Tejpar S, Verslype C, Laurent S. Challenges in the adjuvant treatment for patients with stage II and III colon cancer. ASCO 2006 Educational Book, pp. 179–86.
   Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Benefits and by how much? J Clin Oncol 2004;22:1797–806.
   PubMed Web of Science ®Google Scholar
• Tsai HL, Cheng KI, Lu CY, Kuo CH, Ma CJ, Wu JY, Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection. S Surg Oncol 2008;97:383–7.
   Google Scholar
• Chau I, Allem MJ, Cunningham D, Norman AR, Brown G, Ford HE, The value of routine serum carcino-embryonic antigen measurement and computed tomography in surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004;22:1420–9.
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, MacDonald JS, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:1–15.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348–60.
   PubMed Web of Science ®Google Scholar
• Sørensen NM, Sørensen IV, Würtz Sø, Schrohl AS, Dowell BL, Davis G, Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008;43:774–86.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Stephens RW, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, High preoperative plasma tissue inhibitors of metalloproteinases-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292–9.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, Association between preoperative plasma levels of tissue inhibitor of metalloproteinases-1 and rectal cancer patient survival: A validation study. Eur J Cancer 2004;40:64–72.
   PubMed Web of Science ®Google Scholar
• Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700–10.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006;42:1889–96.
   PubMed Web of Science ®Google Scholar
• Sørensen NM, Byström P, Christensen IJ, Berglund Å, Nielsen HJ, Brünner N, TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of Irinotecan, 5-Fluorouracil and Folinic Acid. Clin Cancer Res 2007;13:4117–22.
   PubMed Web of Science ®Google Scholar
• Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 2004;64:952–61.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229–35.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, McArdle CS, Moesgaard F. The effect of ranitidine on long-term survival in primary colorectal cancer. A 40 months interim analysis. GI Cancer 1998;2:227–33.
   Web of Science ®Google Scholar
• Babson AL. The Cirrus IMMULITE: a new random access automated immunoassay system. J Clin Immunoassay 1991;14:83–8.
   Google Scholar
• Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495–503.
   PubMed Web of Science ®Google Scholar
• Lomholt AF, Frederiksen CB, Christensen LJ, Brünner N, Nielsen HJ. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 2007;380:128–32.
   PubMed Web of Science ®Google Scholar
• Frederiksen CB, Lomholt AF, Lottenburg T, Davis GJ, Dowell BL, Blankenstein MA, Assessment of the biological variation of plasma tissue inhibitor of metallopreteinases-1. Int J Biol Markers 2008;23:42–7.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Brünner N, Christensen IJ, Jensen V, Nielsen HJ. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Lab Invest 2002;62:223–30.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Høgdall CK, Høgdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003;18:170–76.
   PubMed Web of Science ®Google Scholar
• Cooksley S, Hipkiss JB, Tickle SP, Holmes-Levers E, Docherty AJ, Murphy G, Immunoassays for the detection of human collagenase, stromolysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 1990;10:285–91.
   PubMedGoogle Scholar
• Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494–9.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Ghanipour A, Christensen IJ, Brünner N, Glimelius B, Nielsen HJ. Independent prognostic value of plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer. A prospective validation study. J Clin Oncol 2008;26:May 20 suppl; abstract 11072.
   Web of Science ®Google Scholar
• Jeyarajah S, Sutton CD, Miller AS, Hemingway D. Factors that influence the adequacy of total Mesorectal excision for rectal cancer. Colorectal Dis 2007;9:808–15.
   PubMed Web of Science ®Google Scholar
• Påhlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, The Swedish rectal cancer registry. Br J Surg 2007;94:1285–92.
   PubMed Web of Science ®Google Scholar
• Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693–701.
   PubMed Web of Science ®Google Scholar
• den Dulk M, Krijnen P, Marijnen CA, Rutten HJ, van de Poll-Franse LV, Putter H, Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. Eur J Cancer 2008; 44:1710–6.
   PubMed Web of Science ®Google Scholar